Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Novo Nordisk is making yet another bet on ... sets its molecules apart from the competition. Now, Septerna has the validation of a deal with Novo that is worth up to $2.2 billion across an upfront ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

Novo Nordisk said Wednesday that it will work ... a more convenient weight loss treatment to the market. Under the deal, Septerna, which specializes in making small-molecule drugs, is eligible ...

Pharmaceutical giant Novo Nordisk inks a $2.2 billion deal with biotech company Septerna to develop a GLP-1 weight-loss drug in the form of an oral pill.Septerna's stock is skyrocketing by over 60 ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery ... The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline ...

COPENHAGEN, May 14 (Reuters) - Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...